Лечение больных перикардитом противовоспалительными средствами

С момента обновления Европейских рекомендаций по ведению перикардита [1] прошло 8 лет, почти 3 года из которых продолжается пандемия нового коронавируса, изменившего структуру и течение всех кардиологических заболеваний. На сегодняшний день нет сомнений, что доминирующей причиной возникновения перикардита является новый коронавирус SARS-CоV-2. Однако остаются актуальными такие неинфекционные причины, как системные воспалительные заболевания, паранеопластические и постперикардиотомные синдромы, требующие дифференцированной терапевтической стратегии. Для лучшего понимания параметров выбора лечебной схемы в систематическом обзоре рассматривается патогенез развития перикардита с учетом современных представлений об инфекционных и иммунных механизмах, а также высокой вероятности присоединения вируса SARS-CoV-2 к всем остальным имеющимся причинам. Особое внимание уделяется публикациям о диагностике в условиях пандемии и эффективности схем терапии перикардита при воспалении структур сердца, ассоциированных с COVID-19. Проведен обзор литературы в медицинских ресурсах PubMed, Google Scholar, UpToDate с давностью публикаций с 01.1990 по 09.2022 г., затрагивающих вопросы дифференцированной терапии перикардита различными противовоспалительными препаратами.

1. Adler Y., Charron P., Imazio M., Badano L., Barón-Esquivias G., Bogaert J., Brucato A., Gueret P., Klingel K., Lionis C., Maisch B., Mayosi B., Pavie A., Ristic A.D., Sabaté Tenas M., Seferovic P., Swedberg K., Tomkowski W.; ESC Scientific Document Group. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC)Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS). Eur. Heart J. 2015;36(42):2921–2964. DOI: 10.1093/eurheartj/ehv318

2. Сукмарова З.Н., Симоненко В.Б., Ибрагимова Ф.М., Демьяненко А.В. Экссудативный перикардит как новый специфичный симптом SARS-CoV-2: проспективное исследование «случай–контроль». Клиническая медицина. 2021;99(3):192–197. DOI: 10.30629/0023-2149-2021-99-3-192-197

3. Sukmarova Z., Saidova M.A. Echocardiographic phenomenon of pericarditis in patients with severe COVID-19 pneumonia. One-year observation, European Heart Journal — Cardiovascular Imaging. 2022;23(1):jeab289.278. DOI: 10.1093/ehjci/jeab289.278

4. Сукмарова З.Н., Саидова М.А., Овчинников Ю.В. Экссудативный перикардит в патогенезе нарушений ритма сердца при COVID-19: серия клинических случаев. Кардиоваскулярная терапия и профилактика. 2022;21(2):3021. DOI:10.15829/1728-8800-2022-3021

5. Насонов Е.Л. Российские клинические рекомендации. Ревматология. Москва, ГЭОТАР-Медиа, 2017:464. ISBN 978-5-9704-4261-6

6. Furqan M.M., Verma B.R., Cremer P.C., Imazio M., Klein A.L. Pericardial diseases in COVID19: a contemporary review. Curr. Cardiol. Rep. 2021;23(7):90. DOI: 10.1007/s11886-021-01519-x

7. Imazio M., Hoit B.D. Post-cardiac injury syndromes. An emerging cause of pericardial diseases. Int. J. Cardiol. 2013;168:648–652. DOI: 10.1016/j.ijcard.2012.09.052

8. Gouriet F., Levy P.Y., Casalta J.P., Zandotti C., Collart F., Lepidi H., Cautela J., Bonnet J.L., Thuny F., Habib G., Raoult D. Etiology of Pericarditis in a Prospective Cohort of 1162 Cases. Am. J. Med. 2015;128(7):784.e1–8. DOI: 10.1016/j.amjmed.2015.01.040

9. Basso C., Leone O., Rizzo S., De Gaspari M., van der Wal A.C., Aubry M.C., Bois M.C., Lin P.T., Maleszewski J.J., Stone J.R. Pathological features of COVID-19-associated myocardial injury: a multicentre cardiovascular pathology study. Eur. Heart J. 2020;41(39):3827–3835. DOI: 10.1093/eurheartj/ehaa664

10. Huang L., Zhao P., Tang D., Zhu T., Han R., Zhan C., Liu W., Zeng H., Tao Q., Xia L. Cardiac Involvement in Patients Recovered From COVID-2019 Identified Using Magnetic Resonance Imaging. JACC Cardiovasc. Imaging. 2020;13(11):2330–2339. DOI: 10.1016/j.jcmg.2020.05.004

11. Libby P., Lüscher T. COVID-19 is, in the end, an endothelial disease. Eur. Heart J. 2020;41(32):3038–44. DOI: 10.1093/eurheartj/ehaa623

12. Latz E., Xiao T.S., Stutz A. Activation and regulation of the inflammasomes. Nat. Rev. Immunol. 2013;13:397–411. DOI: 10.1038/nri3452

13. Zheng Y.Y., Ma Y.T., Zhang J.Y., Xie X. COVID-19 and the cardiovascular system. Nat. Rev. Cardiol. 2020;17:259–60. DOI: 10.1038/s41569-020-0360-5

14. Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y., Zhang L., Fan G., Xu J., Gu X., Cheng Z., Yu T., Xia J., Wei Y., Wu W., Xie X., Yin W., Li H., Liu M., Xiao Y., Gao H., Guo L., Xie J., Wang G., Jiang R., Gao Z., Jin Q., Wang J., Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. DOI: 10.1016/S0140-6736(20)30183-5

15. Ruan Q., Yang K., Wang W., Jiang L., Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020;46:846–8. DOI: 10.1007/s00134-020-05991-x

16. Chen G., Wu D., Guo W., Cao Y., Huang D., Wang H., Wang T., Zhang X., Chen H., Yu H., Zhang X., Zhang M., Wu S., Song J., Chen T., Han M., Li S., Luo X., Zhao J., Ning Q. Clinical and immunological features of severe and moderate coronavirus disease 2019. J. Clin. Invest. 2020;130(5):2620–9. DOI: 10.1172/JCI137244

17. Fernández-Lázaro D., Sánchez-Serrano N., Mielgo-Ayuso J., García-Hernández J.L., González-Bernal J.J., Seco-Calvo J. Long COVID a New Derivative in the Chaos of SARS-CoV-2 Infection: The Emergent Pandemic? J. Clin. Med. 2021;10(24):5799. DOI: 10.3390/jcm10245799

18. Puntmann V.O., Martin S., Shchendrygina A., Hoffmann J., Ka M.M., Giokoglu E., Vanchin B., Holm N., Karyou A., Laux G.S., Arendt C., De Leuw P., Zacharowski K., Khodamoradi Y., Vehreschild M.J.G.T., Rohde G., Zeiher A.M., Vogl T.J., Schwenke C., Nagel E. Long-term cardiac pathology in individuals with mild initial COVID-19 illness. Nat. Med. 2022. DOI: 10.1038/s41591-022-02000-0

19. Puntmann V. O., D’Cruz D., Smith Z., Pastor A., Choong P., Voigt T., Carr-White G., Sangle S., Schaeffter T., Nagel E. Native myocardial T1 mapping by cardiovascular magnetic resonance imaging in subclinical cardiomyopathy in patients with systemic lupus erythematosus. Circ. Cardiovasc. Imaging. 2013;6:295–301. DOI: 10.1161/CIRCIMAGING.112.000151

20. Carubbi F., Alunno A., Leone S., Di Gregorio N., Mancini B., Viscido A., Del Pinto R., Cicogna S., Grassi D., Ferri C. Pericarditis after SARS-CoV-2 Infection: Another Pebble in the Mosaic of Long COVID? Viruses. 2021;13(10):1997. DOI: 10.3390/v13101997

21. Cao X. COVID-19: immunopathology and its implications for therapy. Nat. Rev. Immunol. 2020;20:269–70. DOI: 10.1038/s41577-020-0308-3

22. Rodrigues T.S, de Sá KSG., Ishimoto A.Y., Becerra A., Oliveira S., Almeida L., Gonçalves A.V., Perucello D.B., Andrade W.A., Castro R., Veras F.P., Toller-Kawahisa J.E., Nascimento D.C., de Lima M.H.F., Silva CMS., Caetite D.B., Martins R.B., Castro I.A., Pontelli M.C., de Barros F.C., do Amaral N.B., Giannini M.C., Bonjorno L.P., Lopes MIF., Santana R.C., Vilar F.C., Auxiliadora-Martins M., Luppino-Assad R., de Almeida SCL., de Oliveira F.R., Batah S.S., Siyuan L., Benatti M.N., Cunha T.M., Alves-Filho J.C., Cunha F.Q., Cunha L.D., Frantz F.G., Kohlsdorf T., Fabro A.T., Arruda E., de Oliveira RDR., Louzada-Junior P., Zamboni D.S. Inflammasomes are activated in response to SARS-CoV-2 infection and are associated with COVID-19 severity in patients. J. Exp. Med. 2021;218(3):e20201707. DOI: 10.1084/jem.20201707

23. Inciardi R.M., Lupi L., Zaccone G., Italia L., Raffo M., Tomasoni D., Cani D.S., Cerini M., Farina D., Gavazzi E., Maroldi R., Adamo M., Ammirati E., Sinagra G., Lombardi C.M., Metra M. Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2019;2020(7):819–24. DOI: 10.1001/jamacardio.2020.1096

24. Tam L.S., Tanaka Y., Handa R., Chang C.C., Cheng Y.K., Isalm N., Li M., Lorenzo J.P., Song Y.W., Yamamoto K., Zeng X., Haq S.A. Care for patients with rheumatic diseases during COVID-19 pandemic: A position statement from APLAR. Int J Rheum Dis. 2020;23(6):717–722. DOI:10.1111/1756-185X.13863

25. Zhou F., Yu T., Du R., Fan G., Liu Y., Liu Z., Xiang J., Wang Y., Song B., Gu X., Guan L., Wei Y., Li H., Wu X., Xu J., Tu S., Zhang Y., Chen H., Cao B. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–62. DOI: 10.1016/S0140-6736(20)30566-3

26. Buckley L.F., Viscusi M.M., Van Tassell B.W., Abbate A. Interleukin-1 blockade for the treatment of pericarditis. Eur. Heart J. Cardiovasc. Pharmacother. 2018;4(1):46–53. DOI: 10.1093/ehjcvp/pvx018

27. Lazaros G., Antonopoulos A.S., Lazarou E., Vlachopoulos C., Vogiatzi G., Vassilopoulos D., Tousoulis D. Age- and sex-based differences in patients with acute pericarditis. Eur. J. Clin. Invest. 2021;51(3):e13392. DOI: 10.1111/eci.13392

28. Imazio M., Gaita F. Acute and recurrent pericarditis. Cardiol. Clin. 2017;35:505–513. DOI: 10.1016/j.ccl.2017.07.004

29. Bonnefoy E., Godon P., Kirkorian G., Fatemi M., Chevalier P., Touboul P. Serum cardiac troponin I and ST-segment elevation in patients with acute pericarditis. Eur. Heart J. 2000;21:832–6. DOI: 10.1053/euhj.1999.1907

30. Diaz-Arocutipa C., Saucedo-Chinchay J., Imazio M. Pericarditis in patients with COVID-19: a systematic review. J. Cardiovasc. Med. (Hagerstown). 2021;22(9):693–700. DOI: 10.2459/JCM.0000000000001202

31. Shah Z.S., Kumar S.A., Patel A.A. Myocarditis and pericarditis in patients with COVID-19. Heart Views. 2020;21(3):209. DOI: 10.4103/HEARTVIEWS

32. Imazio M., Brucato A., Lazaros G., Andreis A., Scarsi M., Klein A., De Ferrari G.M., Adler Y. Anti-inflammatory therapies for pericardial diseases in the COVID-19 pandemic: safety and potentiality. J. Cardiovasc. Med. (Hagerstown). 2020;21(9):625–629. DOI: 10.2459/JCM.0000000000001059

33. Shi S., Qin M., Shen B., Cai Y., Liu T., Yang F., Gong W., Liu X., Liang J., Zhao Q., Huang H., Yang B., Huang C. Association of cardiac injury with mortality in hospitalized patients with COVID19 in Wuhan, China. JAMA Cardiol. 2020;5(7):802–10. DOI: 10.1001/jamacardio.2020.0950

34. Cizgici A.Y., Zencirkiran A.H., Yildiz M. COVID-19 myopericarditis: IT should be kept in mind in today’s conditions. Am. J. Emerg. Med. 2020;38(7):1547.e5–6. DOI: 10.1016/j.ajem.2020.04.080

35. Klein A.L., Abbara S., Agler D.A., Appleton C.P., Asher C.R., Hoit B., Hung J., Garcia M.J., Kronzon I., Oh J.K., Rodriguez E.R., Schaff H.V., Schoenhagen P., Tan C.D., White R.D. American Society of Echocardiography clinical recommendations for multimodality cardiovascular imaging of patients with pericardial disease: endorsed by the Society for Cardiovascular Magnetic Resonance and Society of Cardiovascular Computed Tomography. J. Am. Soc. Echocardiogr. 2013;26:965–1012.e15. DOI: 10.1016/j.echo.2013.06.023

36. Cosyns B., Plein S., Nihoyanopoulos P., Smiseth O., Achenbach S., Andrade M.J., Pepi M., Ristic A., Imazio M., Paelinck B., Lancellotti P.; on behalf of the European Association of Cardiovascular Imaging (EACVI) and European Society of Cardiology Working Group (ESC WG) on Myocardial and Pericardial diseases. European Association of Cardiovascular Imaging (EACVI) position paper: multimodality imaging in pericardial disease. Eur. Heart J. Cardiovasc Imaging. 2014;16:12–31. DOI: 10.1093/ehjci/jeu128

37. Vecchie A., Chiabrando J.G., Dell M.S., Bonaventura A., Mauro A.G., Wohlford G., Van Tassell B.W., Berrocal D.H., Montecucco F., Beutler A., Paolini J.F., Gal T.S., Abbate A. Clinical presentation and outcomes of acute pericarditis in a large urban hospital in the United States of America. Chest. 2020;158(6):2556–67. DOI: 10.1016/j.chest.2020.07.039

38. Imazio M., Brucato A., Maestroni S., Cumetti D., Dominelli A., Natale G., Trinchero R. Prevalence of C-reactive protein elevation and time course of normalization in acute pericarditis: implications for the diagnosis, therapy, and prognosis of pericarditis. Circulation. 2011;123(10):1092–7. DOI: 10.1161/CIRCULATIONAHA.110.986372

39. Mantovani A., Dinarello C.A., Molgora M., Garlanda C. Interleukin-1 and related cytokines in the regulation of inflammation and immunity. Immunity. 2019;50:778–795. DOI: 10.1016/j.immuni.2019.03.012

40. Nigrovic P.A. Interleukin 1 inhibitors: Biology, principles of use, and adverse events. [Electronic resource]. URL: www.uptodate.com (6 January 2020).

41. Alraies M.C., AlJaroudi W., Yarmohammadi H., Yingchoncharoen T., Schuster A., Senapati A., Tariq M., Kwon D., Griffin B.P., Klein A.L. Usefulness of cardiac magnetic resonance-guided management in patients with recurrent pericarditis. Am. J. Cardiol. 2015;115:542–547. DOI: 10.1016/j.amjcard.2014.11.041

42. Imazio M., Demichelis B., Parrini I., Cecchi E., Pomari F., Demarie D., Gaschino G., Ghisio A., Belli R., Trinchero R. Recurrent pain without objective evidence of disease in patients with previous idiopathic or viral acute pericarditis. Am. J. Cardiol. 2004;94:973–975. DOI: 10.1016/j.amjcard.2004.06.046

43. Imazio M., Pivetta E., Palacio Restrepo S., Sormani P., Pedrotti P., Quarta G., Brucato A., Bubbico E., Dal Corso M., Milazzo A., Quattrocchi G., Andriani M., Lobetti Bodoni L., Davini O., Sironi S., Giannattasio C., Giustetto C., Bogaert J., Adler Y., Bucciarelli Ducci C., De Ferrari G.M. Usefulness of cardiac magnetic resonance for recurrent pericarditis. Am. J. Cardiol. 2020;125:146–151. DOI: 10.1016/j.amjcard.2019.09.026

44. Kumar A., Sato K., Yzeiraj E., Betancor J., Lin L., Tamarappoo B.K., Kwon D.H., Hachamovitch R., Klein A.L. Quantitative pericardial delayed hyperenhancement informs clinical course in recurrent pericarditis. JACC Cardiovasc. Imaging. 2017;10(11):1337–1346. DOI: 10.1016/j.jcmg.2016.10.020

45. Kumar S., Khubber S., Reyaldeen R., Agrawal A., Cremer P.C., Imazio M., Kwon D.H., Klein A.L. Advances in Imaging and Targeted Therapies for Recurrent Pericarditis: A Review. JAMA Cardiol. 2022 Aug 17. DOI: 10.1001/jamacardio.2022.2584

46. Chetrit M., Xu B., Kwon D.H., Ramchand J., Rodriguez R.E., Tan C.D., Jellis C.L., Johnston D.R., Renapurkar R.D., Cremer P.C., Klein A.L. Imaging-guided therapies for pericardial diseases. JACC Cardiovasc. Imaging. 2020;13(6):1422–1437. DOI: 10.1016/j.jcmg.2019.08.027

47. Xu B., Kwon D.H., Klein A.L. Imaging of the pericardium: a multimodality cardiovascular imaging update. Cardiol. Clin. 2017;35:491–503. DOI: 10.1016/j.ccl.2017.07.003

48. Wang Z.J., Reddy G.P., Gotway M.B., Yeh B.M., Hetts S.W., Higgins C.B.C.T. CT and MR imaging of pericardial disease. Radiographics. 2003;23(1):S167–S180. DOI: 10.1148/rg.23si035504

49. Chiabrando J.G., Bonaventura A., Vecchié A., Wohlford G.F., Mauro A.G., Jordan J.H., Grizzard J.D., Montecucco F., Berrocal D.H., Brucato A., Imazio M., Abbate A. Management of Acute and Recurrent Pericarditis: JACC State-of-the-Art Review. J. Am. Col.l Cardiol. 2020;75:76. DOI: 10.1016/j.jacc.2019.11.021

50. Boniface N., Kley J., Lisko J., Mikolich B., Mikolich J.R. Non-cardiac chest pain: Is it really? Circulation. 2014;130:A12863

51. Puntmann V.O., Carerj L., Wieters I., Fahim M., Arendt C., Hoffmann J., Shchendrygina A., Escher F., Vasa-Nicotera M., Zeiher A.M., Vehreschild M., Nagel E. Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020;5(11):1265–1273. DOI: 10.1001/jamacardio.2020.3557

52. Imazio M., Brucato A., Derosa F.G., Lestuzzi C., Bombana E., Scipione F., Leuzzi S., Cecchi E., Trinchero R., Adler Y. Aetiological diagnosis in acute and recurrent pericarditis: when and how. J. Cardiovasc. Med. (Hagerstown). 2009;10(3):217–30. DOI: 10.2459/JCM.0b013e328322f9b1

53. Mager A., Berger D., Ofek H., Hammer Y., Iakobishvili Z., Kornowski R. Prodromal symptoms predict myocardial involvement in patients with acute idiopathic pericarditis. Int. J. Cardiol. 2018;270:197–199. DOI: 10.1016/j.ijcard.2018.05.128

54. Imazio M., Belli R., Brucato A., Cemin R., Ferrua S., Beqaraj F., Demarie D., Ferro S., Forno D., Maestroni S., Cumetti D., Varbella F., Trinchero R., Spodick D.H., Adler Y. Efcacy and safety of colchicine for treatment of multiple recurrences of pericarditis (CORP-2): a multicentre, double-blind, placebo-controlled, randomised trial. Lancet. 2014.383:2232–2237. DOI: 10.1016/S0140-6736(13)62709-9

55. Krasic S., Prijic S., Ninic S., Borovic R., Petrovic G., Stajevic M., Nesic D., Dizdarevic I., Djordjevic N., Vukomanovic V. Predictive factors of recurrence after pediatric acute pericarditis. J. Pediatr. (Rio J). 2020;29:S0021-7557(20)30190-X

56. Soler-Soler J., Sagristà-Sauleda J., Permanyer-Miralda G. Relapsing pericarditis. Heart. 2004;90:1364–1368. DOI: 10.1136/hrt.2003.026120

57. Andreis A., Imazio M., Casula M., Avondo S., Brucato A. Recurrent pericarditis: an update on diagnosis and management. Intern. Emerg. Med. 2021;16(3):551–558. DOI: 10.1007/s11739-021-02639-6

58. Bouriche F., Toro A., Negre V., Yvorra S. Acute Pericarditis: Aetiologic Diagnosis and Practical Aspect of the Management. Curr. Probl. Cardiol. 2021;46(4):100769. DOI: 10.1016/j.cpcardiol.2020.100769

59. Bhatia R.T., Marwaha S., Malhotra A. Exercise in the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) era: a question and answer session with the experts endorsed by the section of sports cardiology & exercise of the European Association of Preventive Cardiology (EAPC) Eur. J. Prev. Cardiol. 2020;27(12):1242–1251. DOI: 10.1177/2047487320930596

60. Vecchié A., Del Buono M.G., Chiabrando G.J., Dentali F., Abbate A., Bonaventura A. Interleukin-1 and the NLRP3 Inflammasome in Pericardial Disease. Curr. Cardiol. Rep. 2021;23(11):157. DOI: 10.1007/s11886-021-01589-x

61. Imazio M., Andreis A., Piroli F., Lazaros G., Gattorno M., Lewinter M., Klein A.L., Brucato A. Anti-interleukin 1 agents for the treatment of recurrent pericarditis: a systematic review and meta-analysis. Heart. 2021:heartjnl-2020-318869. DOI: 10.1136/heartjnl-2020-318869

62. Brucato A., Emmi G., Cantarini L., Di Lenarda A., Gattorno M., Lopalco G., Marcolongo R., Imazio M., Martini A., Prisco D. Management of idiopathic recurrent pericarditis in adults and in children: a role for IL-1 receptor antagonism. Intern. Emerg. Med. 2018;13(4):475–489. DOI: 10.1007/s11739-018-1842-x

63. Conte E., Agalbato C., Lauri G, Mushtaq S., Cia A.D., Bonomi A., Guglielmo M., Baggiano A., Gaudenzi-Asinelli M., Colombo G., Sforza C., Agostoni P., Tamborini G., Assanelli E., Pontone G., Pepi M., Brucato A., Andreini D. Cardiac MRI after first episode of acute pericarditis: a pilot study for better identification of high risk patients. Int. J. Cardiol. 2022;354:63–67. DOI: 10.1016/j.ijcard.2022.03.007

64. Cremer P., Lin D., Wheeler A., Abbate A. Cardiac magnetic resonance imaging for guiding decision-making on treatment duration: data from rhapsody, a phase 3 clinical trial of rilonacept in recurrent pericarditis. J. Am. Coll. Cardiol. 2021;77(18) (suppl 1):1302. DOI: 10.1016/S0735-1097(21)02660-7

65. Imazio M., Cecchi E., Demichelis B., Ierna S., Demarie D., Ghisio A., Pomari F., Coda L., Belli R., Trinchero R. Indicators of poor prognosis of acute pericarditis. Circulation. 2007;115(21):2739–44. DOI: 10.1161/CIRCULATIONAHA.106.662114

66. Moore N., Bosco-Levy P., Thurin N., Blin P., Droz-Perroteau C. NSAIDs and COVID-19: A Systematic Review and Meta-Аnalysis. Dru. DOI: 10.1001/jamacardio.2022.2584g. Saf. 2021;44(9):929–938. DOI: 10.1007/s40264-021-01089-5

67. Arunasalam S., Siegel R.J. Rapid resolution of symptomatic acute pericarditis with ketorolac tromethamine: a parenteral nonsteroidal antiinflammatory agent. Am. Heart J. 1993;125:1455.

68. Pope J.E., Anderson J.J., Felson D.T. A metaanalysis of the effects of nonsteroidal antiinflammatory drugs on blood pressure. Arch. Intern. Med. 1993;153:477–84.

69. Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am. J. Med. 1999;106:13S–24S.

70. Imazio M., Cecchi E., Demichelis B., Chinaglia A., Ierna S., Demarie D., Ghisio A., Pomari F., Belli R., Trinchero R. Myopericarditis versus viral or idiopathic acute pericarditis. Heart. 2008;94(4):498–501. DOI: 10.1136/hrt.2006.104067

71. Wood J.E., Mahnensmith R.L. Pericarditis associated with renal failure: evolution and management. Semin. Dial. 2001;14(1):61–6. DOI: 10.1046/j.1525-139x.2001.00017.x

72. Imazio M., Brucato A., Trinchero R., Spodick D., Adler Y. Individualized therapy for pericarditis. Expert Rev. Cardiovasc. Ther. 2009;7(8):965–75. DOI: 10.1586/erc.09.82

73. WHO. Updated: WHO Now Doesn’t Recommend Avoiding Ibuprofen For COVID-19 Symptoms 2020. [Electronic resource]. URL: https://www.scienceale.rt.com/who-recommends-to-avoid-taking-ibuprofen-for-covid-19-symptoms. Accessed 1 Mar 2021.

74. Chen J.S., Alfajaro M.M., Chow R.D., Wei J., Filler R.B., Eisenbarth S.C., Wilen C.B. Non-steroidal anti-inflammatory drugs dampen the cytokine and antibody response to SARS-CoV-2 infection. J. Virol. 2021;95(7):e00014–21. DOI: 10.1128/JVI.00014-21

75. Chen J.S., Alfajaro M.M., Wei J., Chow R.D., Filler R.B., Eisenbarth S.C. Cyclooxgenase-2 is induced by SARS-CoV-2 infection but does not afect viral entry or replication. bioRxiv. 2020. DOI: 10.1101/2020.09.24.312769

76. Kelleni M.T. Early use of non-steroidal anti-infammatory drugs in COVID-19 might reverse pathogenesis, prevent complications and improve clinical outcomes. Biomed. Pharmacother. 2021;133:110982. DOI: 10.1016/j.biopha.2020.110982

77. Chandan J.S., Zemedikun D.T., Thayakaran R., Byne N., Dhalla S., Acosta-Mena D., Gokhale K.M., Thomas T., Sainsbury C., Subramanian A., Cooper J., Anand A., Okoth K.O., Wang J., Adderley N.J., Taverner T., Denniston A.K., Lord J., Thomas G.N., Buckley C.D., Raza K., Bhala N., Nirantharakumar K., Haroon S. Nonsteroidal Antiinflammatory Drugs and Susceptibility to COVID-19. Arthritis Rheumatol. 2021;73(5):731–739. DOI: 10.1002/art.41593

78. Costantino F., Bahier L., Tarancon L.C., Leboime A., Vidal F., Bessalah L., Breban M., D’Agostino M.A. COVID-19 in French patients with chronic infammatory rheumatic diseases: clinical features, risk factors and treatment adherence. Jt. Bone Spine. 2021;88(1):105095. DOI: 10.1016/j.jbspin.2020.105095

79. Imazio M., Bobbio M., Cecchi E., Demarie D., Demichelis B., Pomari F., Moratti M., Gaschino G., Giammaria M., Ghisio A., Belli R., Trinchero R. Colchicine in addition to conventional therapy for acute pericarditis: results of the COlchicine for acute PEricarditis (COPE) trial. Circulation. 2005;112:2012. DOI: 10.1161/CIRCULATIONAHA.105.542738

80. Berman J., Haffajee C.I., Alpert J.S. Therapy of symptomatic pericarditis after myocardial infarction: retrospective and prospective studies of aspirin, indomethacin, prednisone, and spontaneous resolution. Am. Heart J. 1981;101:750

81. Lamontagne F., Agoritsas T., MacDonald H., Zeng L., Amin W., Barragan FAJ., Bausch F.J., Burhan E., Calfee C.S., Cecconi M., Chanda D., Dat V.Q., De Sutter A., Du B., Freedman S., Geduld H., Gee P., Gotte M., Harley N., Hashimi M., Hunt B., Jehan F., Kabra S.K., Kanda S., Kim Y.J., Kissoon N., Krishna S., Kuppalli K., Kwizera A., Lado Castro-Rial M., Lisboa T., Lodha R., Mahaka I., Manai H., Mino G., Nsutebu E., Preller J., Pshenichnaya N., Qadir N., Relan P., Sabzwari S., Sarin R., Shankar-Hari M., Sharland M., Shen Y., Ranganathan S.S., Souza J.P., Stegemann M., Swanstrom R., Ugarte S., Uyeki T., Venkatapuram S., Vuyiseka D., Wijewickrama A., Tran L., Zeraatkar D., Bartoszko J.J., Ge L., Brignardello-Petersen R., Owen A., Guyatt G., Diaz J., Kawano-Dourado L., Jacobs M., Vandvik P.O. A living WHO guideline on drugs for covid-19. BMJ. 2020;370:m3379. DOI: 10.1136/bmj.m3379

82. Li A., Garcia-Bengochea Y., Stechel R., Azari B.M. Management of COVID-19 myopericarditis with reversal of cardiac dysfunction after blunting of cytokine storm: a case report. Eur. Hear J. — Case Rep. 2020;4(FI1):1–6. DOI: 10.1093/ehjcr/ytaa224

83. Lange R.A., Hillis L.D. Clinical practice. Acute pericarditis. N Engl J Med. 2004; 351:2195.

84. Artom G., Koren-Morag N., Spodick D.H., Brucato A., Guindo J., Bayes-de-Luna A., Brambilla G., Finkelstein Y., Granel B., Bayes-Genis A., Schwammenthal E., Adler Y. Pretreatment with corticosteroids attenuates the efficacy of colchicine in preventing recurrent pericarditis: a multi-centre all-case analysis. Eur. Heart J. 2005;26(7):723–7. DOI: 10.1093/eurheartj/ehi197

85. Imazio M., Demichelis B., Parrini I., Cecchi E., Demarie D., Ghisio A., Belli R., Bobbio M., Trinchero R. Management, risk factors, and outcomes in recurrent pericarditis. Am. J. Cardiol. 2005;96(5):736–9. DOI: 10.1016/j.amjcard.2005.04.055

86. Lotrionte M., Biondi-Zoccai G., Imazio M., Castagno D., Moretti C., Abbate A., Agostoni P., Brucato A.L., Di Pasquale P., Raatikka M., Sangiorgi G., Laudito A., Sheiban I., Gaita F. International collaborative systematic review of controlled clinical trials on pharmacologic treatments for acute pericarditis and its recurrences. Am. Heart J. 2010;160(4):662–70. DOI: 10.1016/j.ahj.2010.06.015

87. Russell C.D., Millar J.E., Baillie J.K. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020;395:473–475. DOI: 10.1016/S0140-6736(20)30317-2

88. Peet C.J., Rowczenio D., Omoyinmi E., Papadopoulou C., Mapalo B.R.R., Wood M.R., Capon F., Lachmann H.J. Pericarditis and Autoinflammation: A Clinical and Genetic Analysis of Patients With Idiopathic Recurrent Pericarditis and Monogenic Autoinflammatory Diseases at a National Referral Center. J. Am. Heart Assoc. 2022;11(11):e024931. DOI: 10.1161/JAHA.121.024931

89. Imazio M., Brucato A., Cumetti D., Brambilla G., Demichelis B., Ferro S., Maestroni S., Cecchi E., Belli R., Palmieri G., Trinchero R. Corticosteroids for recurrent pericarditis: high versus low doses: a nonrandomized observation. Circulation. 2008;118(6):667–71. DOI: 10.1161/CIRCULATIONAHA.107.761064

90. Mainzer G., Zaidman I., Hatib I., Lorber A. Intrapericardial steroid treatment for recurrent pericardial effusion in a patient with acute lymphoblastic Leukaemia. Hematol Oncol. 2011;29(4):220-1. DOI: 10.1002/hon.983